Pfizer Inc. announced an update on June 13, 2025, regarding the U.S. Food and Drug Administration's (FDA) review of their supplemental New Drug Application (sNDA) for TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) for treating metastatic castration-resistant prostate cancer (mCRPC). The FDA has approved updated labeling to include final overall survival data for treating adults with homologous recombination repair $(HRR.AU)$ gene-mutated mCRPC. However, the FDA did not grant approval to expand the indication to patients with non-HRR gene mutated mCRPC, citing insufficient evidence for a favorable benefit-risk profile in this subgroup from the Phase 3 TALAPRO-2 trial. Consequently, Pfizer will not pursue an expanded indication for this combination in mCRPC within the United States.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.